Le Lézard
Classified in: Health
Subject: PDT

Lofta Announces The Most Advanced Home Sleep Apnea Test on the Market


LA JOLLA, Calif., March 17, 2019 /PRNewswire-PRWeb/ -- Lofta, Inc., a San Diego based company revolutionizing the home sleep apnea test space announced a commercial agreement with Itamar Medical Ltd. which advances their revolutionary "Complete Path" home sleep apnea testing and treatment program.

Lofta will integrate Itamar's clinically validated diagnostic tool into their streamlined process. The Itamar Medical WatchPAT is a portable sleep diagnostic device that uses peripheral arterial tonometry to enable simple, and accurate testing without the complexity and discomfort of traditional airflow-based tests.

Sleep apnea is a serious condition that deprives the body and brain of much-needed oxygen, and can be a contributing factor to other serious conditions such as heart disease, type 2 diabetes, adult asthma, acid reflux and weight gain.

Lofta brings the most advanced home sleep apnea test on the market to its clients using Itamar Medical's WatchPAT. The Lofta Complete Path takes clients from sleep apnea diagnosis, to sleep apnea treatment in as little as 5-days all from the comfort of home.

CEO, Jay Levitt explains;

"A desire to provide a simple, accurate, reliable solution to those struggling with sleep-disordered breathing and sleep apnea drove the decision to use Itamar's WatchPAT technology. Lofta is committed to making the sleep apnea diagnosis process accessible, and simple to everyone through advanced technology, and a user-friendly approach that has been clinically validated against polysomnography."

"Historically, the process of getting diagnosed and treated for sleep apnea has been challenging for patients who often avoid over-night sleep labs that contribute to the complexity and cost of an already difficult journey. Unfortunately, this means people who have a potentially life-threatening condition go undiagnosed, and untreated."

"Lofta clears the way to better sleep by providing access to sleep apnea screening, testing, online diagnosis and comprehensive treatment support all from one place - the client's home."

Levitt continues, "The WatchPAT is a great match for our clients looking for something quick, easy, and hassle-free. Unlike other sleep tests that require nasal tubes and multiple components, Itamar's device is as easy as putting on a wrist watch. With this in mind, we think it's the perfect tool for Lofta's Complete Path program."

Despite Lofta's commitment to ease and convenience, the company is also committed to all professional best practices, and the highest level of client success, and support.

Lofta's Director of Client Services, Laura Avilez, explains;

"Sleep apnea is a serious condition and should be treated. For this reason, the medical aspects of the Lofta Complete Path are overseen by independent board-certified sleep physicians. We aren't your typical home sleep apnea testing company that ships out tests with little guidance or support. We stay with our clients every step of the way. We love Itamar's WatchPAT because its advanced technology provides quick comprehensive test results. And, our clients appreciate that we can explain the results of their study in a thorough, and accessible way. When people are better informed about their condition, they are vested in their therapy outcomes."

Along these lines, Levitt points out the distinctive aspect of Lofta's business model, which he believes will be enhanced by the Itamar technology, "Lofta's objective is to create long-time relationships with clients by making better sleep easy, and accessible."

About Lofta

Lofta is redefining how people are diagnosed and treated for sleep apnea and chronic snoring with life changing results. By leveraging telemedicine technology, one-on-one customer service, and a consumer-centric approach, Lofta offers sleep apnea testing and treatment solutions on pace with the rapidly changing health and wellness environment - when and where clients need them the most.

Motivated by a desire to streamline the complex process of sleep testing, Lofta makes a better night sleep accessible quickly and easily by removing the obstacles that compound an already exhausting problem - the maze of insurance requirements, inconvenient overnights at a sleep lab, and an all-too-common lack of support - Lofta clears the way to healthy sleep.

Lofta's Complete Path is only part of the company's story. Lofta also seeks to cultivate enduring relationships through its innovative high touch therapy program featuring dedicated sleep coaches and one-on-one support at every step.

As clients continue their treatment journey, Lofta leverages advanced technology to report sleep outcomes daily, and in real-time providing a continuous feedback loop to optimize ongoing therapy. Through high-tech, high-touch engagement, Lofta clients achieve long-term sleep wellness.

All Lofta's signature programs, including its comprehensive e-commerce experience, are available at Buyminicpap.com, and in early 2019 Lofta will launch its new web experience at Lofta.com.

 

SOURCE Lofta


These press releases may also interest you

at 06:50
Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. announced today that Pfizer has...

at 06:45
NGM Biopharmaceuticals, Inc., a clinical stage biotechnology company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients, today announced the appointment of Hsiao D. Lieu, M.D. as...

at 06:35
Alexion Pharmaceuticals, Inc. and Affibody AB today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent...

at 06:18
Weekend Unlimited Inc. ("Weekend" or the "Company") today announced that CEO Mr. Paul Chu spoke at New York City's CannaGather event on Tuesday, March 20. Mr. Chu shared the stage with Richard Carleton, the Chief Executive Officer of the Canadian...

at 06:05
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a...

at 06:05
The global arrhythmia monitoring devices market size is expected to reach USD 8.41 billion in 2025 with a CAGR of 6.8% during the forecast period, according to a new report by Grand View Research, Inc. Continuous R&D activities in the field of...



News published on 17 march 2019 at 08:00 and distributed by: